Shunyou Wang

TL;DR: A clinically relevant ATP site inhibitor of mTOR, INK128, is developed, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure.

TL;DR: INK128 is a potent, selective, and orally active TORC1/2 dual inhibitor positioned to enter clinical development and establishes that transformed lymphocytes are selectively sensitive to active‐site TORC2 inhibitors and further support the development of such compounds for leukemia therapy in addition to solid tumors.

TL;DR: Preclinical data show that PI3K isoform-selective kinase inhibitors as a single agent can provide comparable or superior efficacy than panPI3K inhibitors in tumors with PIK3CA mutation with better tolerability.

TL;DR: Adaptive combination of receptor tyrosine kinase-based anti-angiogenic agents with mTOR kinase inhibitors currently in development may offer a safe and effective therapeutic strategy for renal cancer patients who fail to respond to standard of care therapy.

TL;DR: In this paper, the authors present methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents, resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule.